Orange Book product · Generic (ANDA)
FEBUXOSTAT
FEBUXOSTAT
At a glance
Mar 28, 2022
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 28, 2022
4 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
FEBUXOSTAT
Strength
40MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 206266
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of FEBUXOSTAT
- 2009ULORICBrand (NDA)
NDA 021856 · TAKEDA PHARMS USA
- 2024FEBUXOSTATGeneric (ANDA)
ANDA 205406 · LUPIN
- 2023FEBUXOSTATGeneric (ANDA)
ANDA 211837 · TORRENT
- 2023FEBUXOSTATGeneric (ANDA)
ANDA 210741 · AUROBINDO PHARMA LTD
- 2023FEBUXOSTATGeneric (ANDA)
ANDA 207293 · MACLEODS PHARMS LTD
- 2023FEBUXOSTATGeneric (ANDA)
ANDA 205443 · ZYDUS LIFESCIENCES
- 2021FEBUXOSTATGeneric (ANDA)
ANDA 212924 · ALKEM LABS LTD
- 2020FEBUXOSTATGeneric (ANDA)
ANDA 205374 · DR REDDYS
- 2020FEBUXOSTATGeneric (ANDA)
ANDA 213069 · SUNSHINE
- 2019FEBUXOSTATGeneric (ANDA)
ANDA 210461 · MSN
- 2019FEBUXOSTATGeneric (ANDA)
ANDA 210292 · REGCON HOLDINGS
- 2019FEBUXOSTATGeneric (ANDA)
ANDA 205414 · HIKMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
